Geron Corporation

Item 2.02 Results of Operations and Financial Condition. Geron Corporation (the “Company” or “Geron”) will participate in various meetings with securities analysts and investors during the 43rd Annual J.P. Morgan Healthcare Conference the week of January 13, 2025, and will utilize a presentation handout during those meetings. Such presentation handout discloses that Geron expects to report that (i) net revenue from U.S. sales of RYTELO during the fourth quarter ended December 31, 2024 are expected to be approximately $45 million to $46 million, (ii) operating expenses for the year ended December 31, 2024 are expected to be approximately $250 million to $260 million, and (iii) cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024 are expected to be approximately $500 million. The aforementioned financial information is included on slide #17 of the presentation handout, as furnished in Exhibit 99.1 to this Current Report, and is incorporated herein by reference. The Company has not yet completed its financial close process for the quarter and year ended December 31, 2024. These estimates of the Company’s net revenue, operating expenses and cash, cash equivalents, restricted cash and marketable securities for the applicable 2024 periods presented are preliminary, unaudited and are subject to change upon completion of the Company’s financial statement closing procedures and the audit of the Company’s consolidated financial statements.

Item 7.01 Regulation FD Disclosure. Geron will participate in various meetings with securities analysts and investors during the 43rd Annual J.P. Morgan Healthcare Conference the week of January 13, 2025, and will utilize a presentation handout during those meetings. The presentation handout, together with a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation handout, is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The presentation handout will also be made available in the Investors section of Geron’s website, located at www.geron.com. The information contained in Items 2.02 and 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act, and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.